Jin X - Search Results

1

Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.

Liu XY, Ma D, Xu XE, Jin X, Yu KD, Jiang YZ, Shao ZM. Liu XY, et al. Among authors: jin x. Theranostics. 2018 Dec 8;8(22):6386-6399. doi: 10.7150/thno.29164. eCollection 2018. Theranostics. 2018. PMID: 30613307 Free PMC article.

2

Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study.

Jin X, Jiang YZ, Chen S, Yu KD, Shao ZM, Di GH. Jin X, et al. Oncotarget. 2015 Apr 20;6(11):9600-11. doi: 10.18632/oncotarget.3292. Oncotarget. 2015. PMID: 25826079 Free PMC article.

3

Luminal B subtype: a key factor for the worse prognosis of young breast cancer patients in China.

Tang LC, Jin X, Yang HY, He M, Chang H, Shao ZM, Di GH. Tang LC, et al. Among authors: jin x. BMC Cancer. 2015 Mar 29;15:201. doi: 10.1186/s12885-015-1207-z. BMC Cancer. 2015. PMID: 25885213 Free PMC article.

4

Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated mRNA-lncRNA Signature with Predictive and Prognostic Value.

Jiang YZ, Liu YR, Xu XE, Jin X, Hu X, Yu KD, Shao ZM. Jiang YZ, et al. Among authors: jin x. Cancer Res. 2016 Apr 15;76(8):2105-14. doi: 10.1158/0008-5472.CAN-15-3284. Epub 2016 Mar 3. Cancer Res. 2016. PMID: 26921339

5

Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer.

Liu YR, Jiang YZ, Xu XE, Yu KD, Jin X, Hu X, Zuo WJ, Hao S, Wu J, Liu GY, Di GH, Li DQ, He XH, Hu WG, Shao ZM. Liu YR, et al. Among authors: jin x. Breast Cancer Res. 2016 Mar 15;18(1):33. doi: 10.1186/s13058-016-0690-8. Breast Cancer Res. 2016. PMID: 26975198 Free PMC article.

6

Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin.

Wang RX, Chen S, Jin X, Shao ZM. Wang RX, et al. Among authors: jin x. Sci Rep. 2016 Jul 18;6:30091. doi: 10.1038/srep30091. Sci Rep. 2016. PMID: 27426056 Free PMC article.

7

A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer.

Jin X, Jiang YZ, Chen S, Yu KD, Ma D, Sun W, Shao ZM, Di GH. Jin X, et al. BMC Cancer. 2016 Aug 5;16:606. doi: 10.1186/s12885-016-2652-z. BMC Cancer. 2016. PMID: 27495967 Free PMC article.

8

A Nomogram for Predicting the Pathological Response of Axillary Lymph Node Metastasis in Breast Cancer Patients.

Jin X, Jiang YZ, Chen S, Shao ZM, Di GH. Jin X, et al. Sci Rep. 2016 Aug 31;6:32585. doi: 10.1038/srep32585. Sci Rep. 2016. PMID: 27576704 Free PMC article.

9

Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis.

Wang RX, Chen S, Jin X, Chen CM, Shao ZM. Wang RX, et al. Among authors: jin x. Breast Cancer Res Treat. 2017 Jan;161(2):259-267. doi: 10.1007/s10549-016-4064-9. Epub 2016 Nov 24. Breast Cancer Res Treat. 2017. PMID: 27885439

10

DSCAM-AS1 regulates the G₁ /S cell cycle transition and is an independent prognostic factor of poor survival in luminal breast cancer patients treated with endocrine therapy.

Sun W, Li AQ, Zhou P, Jiang YZ, Jin X, Liu YR, Guo YJ, Yang WT, Shao ZM, Xu XE. Sun W, et al. Among authors: jin x. Cancer Med. 2018 Dec;7(12):6137-6146. doi: 10.1002/cam4.1603. Epub 2018 Nov 14. Cancer Med. 2018. PMID: 30430768 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13,795 results

Search Page

Filters